321 related articles for article (PubMed ID: 34889355)
1. Minimizing cardiac toxicity in children with acute myeloid leukemia.
Narayan HK; Getz KD; Leger KJ
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):368-375. PubMed ID: 34889355
[TBL] [Abstract][Full Text] [Related]
2. Rationale and design of the Children's Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy.
Leger KJ; Robison N; Narayan HK; Smith AM; Tsega T; Chung J; Daniels A; Chen Z; Englefield V; Demissei BG; Lefebvre B; Morrow G; Dizon I; Gerbing RB; Pabari R; Getz KD; Aplenc R; Pollard JA; Chow EJ; Tang WHW; Border WL; Sachdeva R; Alonzo TA; Kolb EA; Cooper TM; Ky B
Front Cardiovasc Med; 2023; 10():1286241. PubMed ID: 38107263
[TBL] [Abstract][Full Text] [Related]
3. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients.
Seif AE; Walker DM; Li Y; Huang YS; Kavcic M; Torp K; Bagatell R; Fisher BT; Aplenc R
Pediatr Blood Cancer; 2015 Apr; 62(4):704-9. PubMed ID: 24668949
[TBL] [Abstract][Full Text] [Related]
4. Cardiac complications in childhood cancer survivors treated with anthracyclines.
Franco VI; Lipshultz SE
Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
Shaikh F; Dupuis LL; Alexander S; Gupta A; Mertens L; Nathan PC
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598513
[TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane Significantly Reduces Anthracycline-induced Cardiotoxicity in Pediatric Solid Tumor Patients: A Systematic Review.
Liesse K; Harris J; Chan M; Schmidt ML; Chiu B
J Pediatr Hematol Oncol; 2018 Aug; 40(6):417-425. PubMed ID: 29432315
[TBL] [Abstract][Full Text] [Related]
7. The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
Sánchez-Medina J; Gonzalez-Ramella O; Gallegos-Castorena S
J Pediatr Hematol Oncol; 2010 May; 32(4):294-7. PubMed ID: 20404753
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
9. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
[TBL] [Abstract][Full Text] [Related]
10. Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
Getz KD; Sung L; Alonzo TA; Leger KJ; Gerbing RB; Pollard JA; Cooper T; Kolb EA; Gamis AS; Ky B; Aplenc R
J Clin Oncol; 2020 Jul; 38(21):2398-2406. PubMed ID: 32343641
[TBL] [Abstract][Full Text] [Related]
11. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
12. A strategy to reduce cumulative anthracycline exposure in low-risk pediatric acute myeloid leukemia while maintaining favorable outcomes.
Sabnis HS; Minson KA; Monroe C; Allen K; Metts JL; Cooper TM; Woods WG; Castellino SM; Keller FG
Leuk Res; 2020 Sep; 96():106421. PubMed ID: 32683126
[TBL] [Abstract][Full Text] [Related]
13. Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.
Wu V
J Pediatr Oncol Nurs; 2015; 32(3):178-84. PubMed ID: 25366577
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
16. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.
Marty M; Espié M; Llombart A; Monnier A; Rapoport BL; Stahalova V;
Ann Oncol; 2006 Apr; 17(4):614-22. PubMed ID: 16423847
[TBL] [Abstract][Full Text] [Related]
17. Prevention of cardiotoxicity among survivors of childhood cancer.
Hutchins KK; Siddeek H; Franco VI; Lipshultz SE
Br J Clin Pharmacol; 2017 Mar; 83(3):455-465. PubMed ID: 27591829
[TBL] [Abstract][Full Text] [Related]
18. Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients.
Kim H; Kang HJ; Park KD; Koh KN; Im HJ; Seo JJ; Lee JW; Chung NG; Cho B; Kim HK; Lee JM; Hah JO; Lee JA; Lee YH; Park SK; Baek HJ; Kook H; Kim JY; Kim HS; Kim HM; Chueh HW; Park M; Yoon HS; Lee MJ; Choi HS; Ahn HS; Kawano Y; Park JW; Hahn S; Shin HY
Cancer Res Treat; 2019 Jan; 51(1):357-367. PubMed ID: 29764117
[TBL] [Abstract][Full Text] [Related]
19. Cardiotoxicity and cardioprotection in childhood cancer.
Lipshultz SE; Sambatakos P; Maguire M; Karnik R; Ross SW; Franco VI; Miller TL
Acta Haematol; 2014; 132(3-4):391-9. PubMed ID: 25228565
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular disease in survivors of childhood cancer.
Bansal N; Amdani SM; Hutchins KK; Lipshultz SE
Curr Opin Pediatr; 2018 Oct; 30(5):628-638. PubMed ID: 30124579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]